Astonea Labs Ltd
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies[1]
- Market Cap ₹ 340 Cr.
- Current Price ₹ 323
- High / Low ₹ 369 / 118
- Stock P/E 75.1
- Book Value ₹ 54.4
- Dividend Yield 0.00 %
- ROCE 10.5 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 5.94 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 47.9 days to 74.2 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 98 | 148 | |
| 82 | 134 | |
| Operating Profit | 15 | 14 |
| OPM % | 16% | 9% |
| 0 | 1 | |
| Interest | 4 | 3 |
| Depreciation | 5 | 5 |
| Profit before tax | 7 | 6 |
| Tax % | 24% | 20% |
| 5 | 5 | |
| EPS in Rs | 6.93 | 4.30 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 51% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 103% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 8 | 11 |
| Reserves | 11 | 47 |
| 53 | 43 | |
| 32 | 46 | |
| Total Liabilities | 103 | 146 |
| 26 | 31 | |
| CWIP | 4 | 8 |
| Investments | 0 | 6 |
| 73 | 101 | |
| Total Assets | 103 | 146 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 9 | -14 | |
| -11 | -20 | |
| 2 | 34 | |
| Net Cash Flow | -0 | 0 |
| Free Cash Flow | -2 | -28 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 70% | -88% |
Ratios
Consolidated / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 142 | 129 |
| Inventory Days | 161 | 125 |
| Days Payable | 144 | 150 |
| Cash Conversion Cycle | 159 | 103 |
| Working Capital Days | 22 | 74 |
| ROCE % | 11% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Cosmetics Capacity Utilization - Creams % |
|
||
| Cosmetics Monthly Production Volume - Creams Million units/month |
|||
| Export Revenue as % of Total Revenue % |
|||
| Own Brand Sales as % of Total Revenue % |
|||
| Pharma Capacity Utilization - Tablets % |
|||
| Pharma Monthly Production Volume - Tablets Million units/month |
|||
| Pharmaceuticals Revenue as % of Total Revenue % |
|||
| Top 5 Customer Concentration % of revenue |
|||
Extracted by Screener AI
Documents
Announcements
-
Intimation Regarding Change In The Corporate Identification Number (CIN) Of The Company Consequent Upon Alteration Of The Object Clause Of The Memorandum Of Association
- MCA registered revised CIN after AGM-approved alteration of object clause on 9 October 2026.
-
Incorporation Of Proposed Subsidiary- Longevity Science Private Limited
- Astonea Labs incorporated Longevity Science Pvt Ltd on 8 Oct 2026; plans 51% subscription for Rs5.1 lakh.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended 30 September 2026; no demat/remat requests received.
- Closure of Trading Window
- Resubmission Of Financial Results For The Half Year Ended 31.03.2025 In Response To BSE Communication
Business Overview[1]
Astonea Labs is a healthcare and pharmaceutical company with capabilities across pharmaceutical manufacturing, contract development and manufacturing, and cosmetic and personal care manufacturing. Its operations are supported by R&D capabilities, scientific expertise, manufacturing infrastructure and quality systems, serving both domestic and international markets.